In order to gain knowledge on what might drive the response to monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) in advanced urothelial cancer, and how this compares to other kinds of cancers, we performed an in-depth study of whole exome and RNA sequencing data from a cohort composed of 27 patients treated with ICIs targeting PD-1/PD-L1 from Hospital del Mar in Barcelona (Spain). Here, PDCD1 is linked to cancer.